US 11,890,145 B2
Adhesion-preventing composition
Taichi Ito, Tokyo (JP); Seiichi Ohta, Tokyo (JP); Norihiro Kokudo, Tokyo (JP); Mitsuko Isaji, Tokyo (JP); and Satoshi Shimizu, Tokyo (JP)
Assigned to The University of Tokyo, Tokyo (JP); and Mochida Pharmaceutical Co., Ltd., Tokyo (JP)
Filed by Mochida Pharmaceutical Co., Ltd., Tokyo (JP); and The University of Tokyo, Tokyo (JP)
Filed on Aug. 26, 2022, as Appl. No. 17/896,474.
Application 17/896,474 is a continuation of application No. 16/316,097, granted, now 11,464,597, previously published as PCT/JP2017/025614, filed on Jul. 13, 2017.
Claims priority of application No. 2016-138666 (JP), filed on Jul. 13, 2016.
Prior Publication US 2023/0145308 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 90/00 (2016.01); A61L 31/14 (2006.01); A61L 31/12 (2006.01); A61L 31/04 (2006.01)
CPC A61B 90/08 (2016.02) [A61L 31/04 (2013.01); A61L 31/12 (2013.01); A61L 31/128 (2013.01); A61L 31/14 (2013.01); A61L 31/146 (2013.01); A61B 2090/0816 (2016.02); A61L 2420/08 (2013.01)] 9 Claims
 
1. A method for preventing an adhesion, comprising applying a sterilized biocompatible sponge-like laminate that includes first and second sponge-like layers containing low-endotoxin monovalent metal salts of alginic acid which are at least partially crosslinked with a curing agent, wherein a weight average molecular weight of the monovalent metal salt of alginic acid in the first layer is 10,000-2,000,000, a weight average molecular weight of the monovalent metal salt of alginic acid in the second layer is 1,000-1,000,000, the weight average molecular weights are measured by GPC-MALS method following a decrosslinking treatment, and the weight average molecular weight of the monovalent metal salt of alginic acid in the first layer is higher than the weight average molecular weight of the monovalent metal salt of alginic acid in the second layer, to a subject in need of adhesion prevention.